Mathias Castonguay

Dr. Mathias Castonguay

Université de Montréal, Montréal, Quebec, Canada
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in eClinicalMedicine
Verified
Journal Article
Open access
IMIsabella Michelon
Isabella Michelon
MVMaysa Vilbert
Maysa Vilbert
IPIsabella Silveira Pinheiro
Isabella Silveira Pinheiro
ICIsabela Lino Costa
Isabela Lino Costa
CLCecilia Fernandes Lorea
Cecilia Fernandes Lorea
Stéphanie FortéStéphanie Forté
Stéphanie Forté
Clinical manifestations and severity of SARS-CoV-2 infection in individuals with sickle cell disease (SCD) and sickle cell trait (SCT) are not well understood yet. We performed a systematic review and meta-analysis to assess COVID-19 outcomes in individuals with SCD or SCT compared to individuals without sickle cell disease or trait. An electronic search on PubMed, Embase, and Cochrane Library was performed on August 3, 2023. Two authors (IFM and ISP) independently screened (IFM and ISP) and extracted data (IFM and ILC) from included studies. Main exclusion criterion was the absence of the non-SCD/SCT group. Exposure effects for binary endpoints were compared using pooled odds ratio (OR) with 95% confidence intervals (CI). I2 statistics was used to assess the heterogeneity and DerSimonian and Laird random-effects models were applied for all analyses to minimize the impact of differences in methods and outcomes definitions between studies. The overall quality of evidence was assessed using the GRADE system. Review Manager 5.4 and R software (v4.2.2) were used for statistical analyses. Registered with PROSPERO, CRD42022366015. Overall, 22 studies were included, with a total of 1892 individuals with SCD, 8677 individuals with SCT, and 1,653,369 individuals without SCD/SCT. No difference in all-cause mortality was seen between SCD/SCT and non-SCD/SCT (OR 1.18; 95% CI 0.78–1.77; p = 0.429; I2 = 82%). When considering only studies adjusted for confounders (8 studies), patients with SCD/SCT were shown to be at increased risk of death (OR 1.86; 95% CI 1.30–2.66; p = 0.0007; I2 = 34%). No significant difference was seen between individuals with SCD and SCT (p = 0.863). The adjusted for confounders analysis for hospitalisation revealed higher rates for the SCD (OR 5.44; 95% CI 1.55–19.13; p = 0.008; I2 = 97%) and the SCT groups (OR 1.31; 95% CI 1.10–1.55; p = 0.002; I2 = 0) compared to the non-SCD/SCT population. Moreover, it was significantly higher for the SCD group (test for subgroup difference; p = 0.028). Our findings suggest that patients with SCD or SCT may present with a higher mortality and hospitalisation rates due to COVID-19 infection. None.

4 May 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Mathias CastonguayMathias Castonguay
Mathias Castonguay
Rola El SayedRola El Sayed
Rola El Sayed
CRCorentin Richard
Corentin Richard
MVMarie-France Vachon
Marie-France Vachon
RNRami Nassabein
Rami Nassabein
MTMustapha Tehfe
Mustapha Tehfe
Background: Public health measures have imposed drastic reductions in cancer screening programs at the beginning of the COVID-19 pandemic, with an unknown impact on the diagnosis and staging of colorectal cancer (CRC). Methods: Newly diagnosed CRC cases at the Centre Hospitalier de l’Université de Montréal (CHUM) were divided into two groups according to the timeline: pre-pandemic (1 January 2018–12 March 2020), and pandemic (13 March 2020–30 June 2021) periods. Colonoscopy, surgery, and staging at diagnosis during the pandemic period were compared to the pre-pandemic period. Results: 254 CRC diagnoses were made during the pre-pandemic period in comparison to 125 during the pandemic period. Mean diagnosis rates were lower in the pandemic period (7.8 vs. 9.8 diagnoses/month, p = 0.048). Colonoscopy deadlines were less respected in the pandemic period (51.7% vs. 38.3%, p = 0.049). The rate of elective surgery did not differ (2.9 vs. 3.5 surgeries/month, p = 0.39) and mean delays were similar (58.6 vs. 60.4 days, p = 0.77). Stages at diagnosis did not differ (p = 0.17). Most of the delayed colonoscopies led to a stage 0 or I CRC (p = 0.2). Conclusion: In our center, the COVID-19 pandemic resulted in a decreased rate of CRC diagnosis and increased endoscopic delays without affecting the rate of advanced stage disease. Delays to surgery were quite similar once the CRC diagnosis was established.

3 May 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
Stéphanie FortéStéphanie Forté
Stéphanie Forté
FBFlorence Blais
Florence Blais
Mathias CastonguayMathias Castonguay
Mathias Castonguay
NFNafanta Fadiga
Nafanta Fadiga
MFMireille Fortier-St-Pierre
Mireille Fortier-St-Pierre
KKKevin H.M. Kuo
Kevin H.M. Kuo
Black individuals in the United States are at an increased risk for dementia.1,2 Adults with sickle cell disease (SCD), in particular, disproportionally experience cognitive dysfunction.3 Sickle cell disease is a genetic condition that occurs in about 1 in every 365 births in the Black or African American population.4 Substitution of glutamine by valine in position 6 of the β-globin is responsible for the irreversible sickling of red blood cells, hemolysis, and vaso-occlusion under prolonged deoxygenated conditions. This sickling leads to anemia, pain crises, and systemic vasculopathy that can culminate in stroke, silent cerebral infarcts, reduced cerebral vascular reserve, and cognitive dysfunction.5,6 Precise estimates on the prevalence of dementia and mild neurocognitive disorder (NCD) in adults with SCD are lacking, but they could be as high as 33%.3 In comparison, 564 000 persons (<2% of the population) in Canada were estimated to live with dementia in 2016.7 The cognitive domains associated with SCD are perceptual reasoning, verbal reasoning, executive function, working memory, attention, and processing speed.8 These deficits can have implications for quality of life, social functioning, school performance, and employment.9

12 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Mathias CastonguayMathias Castonguay
Mathias Castonguay
NDNawar Dakhallah
Nawar Dakhallah
Justin DesrochesJustin Desroches
Justin Desroches
MCMarie-Laure Colaiacovo
Marie-Laure Colaiacovo
CJCamille Jimenez-Cortes
Camille Jimenez-Cortes
Stéphanie FortéStéphanie Forté
Stéphanie Forté
Background: Patients with sickle cell disease (SCD) are considered at higher risk of severe COVID-19 infection. However, morbidity and mortality rates are variable among countries. To date, there are no published reports that document outcomes of SCD patients with COVID-19 in Canada. Methods: A web-based registry was implemented in June 2020 capturing outcomes of SCD patients with COVID-19 from March 2020 to April 2022 and comparing them to the general population of Quebec, Canada. Results: After 24 months of the pandemic, 185 SCD patients with confirmed SARS-CoV-2 infection were included in the registry. Overall, the population was young (median age 12 years old) and had few comorbidities. No deaths were reported. Risk of hospitalization and admission to intensive care unit (ICU) because of COVID-19 was higher in patients with SCD than in the general population (relative risks (RR) 5.15 (95% confidence interval (95% CI) 3.84–6.91), p ˂ 0.001 and 4.56 (95% CI 2.09–9.93) p ˂ 0.001). A history of arterial hypertension or acute chest syndrome in the past 12 months was associated with a higher risk of severe disease (RR = 3.06 (95% CI 1.85–5.06) p = 0.008 and 2.27 (95% CI 1.35–3.83) p = 0.01). Hospitalized patients had lower hemoglobin F than non-hospitalized patients (12% vs. 17%, p = 0.02). For those who had access to vaccination at the time of infection, 25 out of 26 patients were adequately vaccinated and had mild disease. Conclusions: The SCD population is at higher risk of severe disease than the general population. However, we report favorable outcomes as no deaths occurred. Registries will continue to be critical to document the impact of novel COVID-19 specific therapy and vaccines for the SCD population.

28 January 2025 in Transfusion
Verified
Journal Article
Open access
Mathias CastonguayMathias Castonguay
Mathias Castonguay
LBLéa Bernard
Léa Bernard
MCMarylène Corriveau
Marylène Corriveau
ACAnik Castonguay
Anik Castonguay
GQGeneviève Quenneville
Geneviève Quenneville
MBMelissa Boileau
Melissa Boileau
Background: Cold agglutinin disease (CAD) or syndrome (CAS) can be particularly challenging when autologous stem cell transplant (ASCT) is needed. Standard peripheral blood stem cell (PBSC) collection and manipulation involve ex vivo blood manipulations at lower than body temperature, predisposing to agglutination during graft collection, handling, processing, and infusion.Study Design and Methods: We describe the first case of ASCT for relapsing lymphoma in a patient with high‐titer CAD requiring anti‐complement therapy and chronic transfusion. To prevent agglutination, five therapeutic plasma exchange sessions were performed prior to PBSC collection. Optimal thermal conditions were maintained using various approaches to increase the temperature of the room, venous return lines, and the apheresis device. Ex vivo graft manipulation was conducted under similar conditions. An infusion test was performed with a fraction of the graft a month prior to ASCT to confirm tolerability.Results: The infusion test was performed without complications. A month later, the patient was admitted for ASCT. The aplasia phase was particularly challenging, as the patient experienced a rapid drop in hemoglobin levels due to hemolysis without compensatory reticulocytosis. Twelve months after ASCT, chronic hemolysis persists, but the patient is now transfusion‐free, and the lymphoma remains in remission.Discussion: Performing ASCT in patients with clinically significant CAS or CAD is challenging but can be done safely. Strong coordination between the apheresis team, cell therapy laboratory, and clinical unit is paramount to the success of this procedure. The experience gained from this case may also be applicable to other cell therapy procedures.

24 December 2021 in Blood
Verified
Journal Article
Open access
Mathias CastonguayMathias Castonguay
Mathias Castonguay
NDNawar Dakhallah
Nawar Dakhallah
MCMarie-Laure Colaiacovo
Marie-Laure Colaiacovo
CJCamille Jimenez-Cortes
Camille Jimenez-Cortes
JDJustin Desroches
Justin Desroches
SFStéphanie Forté
Stéphanie Forté
Introduction Approximately 1500 people live with sickle cell disease (SCD) in the province of Quebec, Canada. Public health has recognized these patients as immunocompromised. SCD patients may be at higher risk of developing severe COVID-19 infection due to their underlying pro-inflammatory and thrombogenic state, splenic dysfunction and secondary organopathies. Descriptions about disease severity and mortality rates in SCD vary widely. From the SECURE-SCD registry, Mucalo et al. recently reported a 0.3% and 4.7% mortality rate in children and adults, respectively. In the French registry, Arlet and colleagues reported a 2.4% death rate among those hospitalized with COVID-19 and SCD, not different from the general population. As a result, the COVID-19 morbidity and mortality rates among the SCD population remain uncertain. Objectives The primary objectives of our study are to describe the epidemiology, baseline characteristics and clinical outcomes of SCD patients with COVID-19 infection in the province of Quebec. In addition, we aim to identify risk factors for hospitalization and severe forms of COVID-19. Methods We built a web-based SCD-COVID-19 registry regrouping 7 adult and 4 paediatric tertiary care hospitals in the province of Quebec in June 2020. All SCD patients with a confirmed SARS-CoV-2 infection by PCR test were included in the study. We compared the prevalence of infection and hospitalization rates of SCD patients to the general population of Quebec using the epidemiological data from the INSPQ (National Institute of Public Health of Quebec) public database. We retrospectively analyzed data included between March 11, 2020 to March 1, 2021. Relative risk was calculated using bilateral association measures (exact fisher, mid-p or chi-squared tests, as appropriate) to compare the incidence of infection and hospitalization of SCD patients to the population of Quebec and to assess risk factors of hospitalization among SCD patients. Results During the first 12 months of the pandemic, 74 patients were included in the registry. The male to female ratio was 1:1.12. Median age was 23 years, ranging from 8 months to 68 years old. SS-Sbeta 0 genotypes were present in 51% of cases, while 49% were SC or Sbeta +. The majority of patients were on disease modifying therapy: 54% were on hydroxyurea and 17.5% on exchange transfusion therapy. The incidence of reported COVID-19 infection was significantly higher in SCD patients compared to the general population (4.9% vs. 3.5% p=0,002) (Table 1). Even more strikingly, SCD had rate of hospitalization 10-times greater than the general population (33.8 vs 3.2%, p<0,001). Nevertheless, the risk of admission to the intensive care unit was similar between SCD patients and the general population (24.0% vs. 24.1%, p=0.99). No death was recorded amongst SCD patients with COVID-19 compared to a death rate in the general population in Quebec of less than 70 years old of 48-78 for 100 000 infections (male-female). A history of acute chest syndrome (ACS) in the last year (OR 2.6 [1.5-4.6], p=0.04) and arterial hypertension (OR 3.3 [2.3-4.8], p=0.01) were associated with a higher risk of hospitalization (Table 2). On the other hand, there was no statistically significant association with age, sex, genotype, ABO blood group, baseline SCD therapy, or other comorbidities (chronic renal disease, obesity, pulmonary hypertension, chronic lung disease and previous admission to ICU) in our cohort. Conclusions Similar to other reports, we found that SCD patients were at much greater risk of hospitalization compared to the general population. We however found no increased risk of mortality or disease complication. This contrasts with results from other registries. A history of ACS and hypertension were associated with a higher risk of hospitalization. Whether social determinants of health could explain some of the outcome variability between different countries merit further investigation. Furthermore, we believe that registries are critical to monitor the impact of preventive measures. As vaccination is ongoing, it will be important to consider its impact on hospitalization and death rate among SCD population. Recruitment to the registry is ongoing and updated data will be presented at the meeting.